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CXCR4Alleviatingmyocardial injury associatedwith ST elevationmyocardial infarction is central to improving the glob-
al burden of coronary heart disease. The chemokine stromal cell-derived factor 1α (SDF-1α) has dual potential
beneﬁt in this regard. Firstly, SDF-1α is up-regulated in experimental and clinical studies of acutemyocardial in-
farction (AMI) and regulates stem cell migration to sites of injury. SDF-1α delivery to themyocardium after AMI
is associated with improved stem cell homing, angiogenesis, and left ventricular function in animal models, and
improvements in heart failure and quality of life in humans. Secondly, SDF-1αmay have a role in remote ischae-
mic conditioning (RIC), the phenomenon whereby non-lethal ischaemia–reperfusion applied to an organ or
tissue remote from the heart protects the myocardium from lethal ischaemia–reperfusion injury (IRI). SDF-1α
is increased in the serum of rats subjected to RIC and protects against myocardial IRI in ex vivo studies. Despite
these potential pleiotropic effects, a limitation of SDF-1α is its short plasmahalf-life due to cleavage by dipeptidyl
peptidase-4 (DPP-4). However, DPP-4 inhibitors increase the half-life of SDF-1α by preventing its degradation
and are also protective against lethal IRI. In summary, SDF-1 potentially delivers a ‘two-pronged’ defence of
the myocardium: acutely protecting it from IRI while simultaneously stimulating repair by recruiting stem
cells to the site of injury. In this article we examine the evidence for acute and chronic cardioprotective roles of
SDF-1α and discuss potential therapeutic manipulations of this mechanism with DPP-4 inhibitors to protect
against lethal tissue injury in the clinical setting.
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Coronary heart disease is the leading cause of death worldwide,
accounting for an estimated 7.3 million deaths per year (“Global Atlas
on Cardiovascular Disease Prevention and Control”). Untreated, mor-
tality following ST-elevation myocardial infarction (STEMI) may benﬂict of interest including any
s or organisations within three
inﬂuence, or be perceived toas high as 15% and strategies to mitigate the deleterious effects of
STEMI are therefore paramount (Gibson, 2004). Early reperfusion by
primary percutaneous coronary intervention (PPCI) is the most effec-
tive strategy for reducing infarct size and improving clinical outcome
(Keeley et al., 2003 Gibson, 2004). Other important therapeutic targets
include platelet aggregation, subsequent myocardial dysfunction and
secondary prevention, including statin therapy. Overall, 30 day mortal-
ity following PPCI in the UK is now 6.5% (“BCIS Audit Returns 2012:
Adult Interventional Procedures”). Another potential target is the inju-
ry inﬂicted by the therapeutic restoration of blood ﬂow, known as is-
chaemia–reperfusion injury (IRI), which may account for up to 50%
306 D.I. Bromage et al. / Pharmacology & Therapeutics 143 (2014) 305–315of ﬁnal infarct size (Braunwald & Kloner, 1985; Piper et al., 1998; Staat
et al., 2005; Yellon & Hausenloy, 2007). The chemokine stromal cell-
derived factor 1α (SDF-1α) potentially delivers a ‘two-pronged’ de-
fence of the myocardium in this regard: acutely protecting the myocar-
dium from IRI while simultaneously stimulating myocardial repair by
recruiting stem cells to the site of injury.
SDF-1α is known to play a central role in stem cell homing, reten-
tion, survival, proliferation, cardiomyocyte repair, angiogenesis and
ventricular remodelling following myocardial infarction (Kucia et al.,
2004; Cheng et al., 2008; Saxena et al., 2008; Tang et al., 2009; Zaruba
et al., 2009; Jujo et al., 2010; Takahashi, 2010; Tang et al., 2010;
Zaruba & Franz, 2010; Ghadge et al., 2011; Kanki et al., 2011; Dong
et al., 2012; Penn et al., 2012). It acts as the unique ligand for its receptor
CXCR4 and the SDF-1–CXCR4 axis is up-regulated in both experimental
and clinical studies of myocardial infarction (Zaruba & Franz, 2010).
SDF-1α–CXCR4has been utilised to target stem cells to ischaemic tissue,
thereby improving left ventricular (LV) dimensions and function (Misao
et al., 2006; Sasaki et al., 2007; Saxena et al., 2008; Tang et al., 2010). Im-
portantly, the SDF-1α–CXCR4 signalling axis exerts these effects via a
Gα1 dependentmechanismand activation of phosphoinositide 3 kinase
(PI3K), mitogen activated protein kinase (MAPK), and Janus kinase
(JAK)-signal transducer and activator of transcription (STAT) signalling.
These signalling pathways are the same pathways that it is postu-
lated are responsible for the protection against IRI conferred by all
forms of conditioning such as pre, post and remote ischaemic condi-
tioning (Hausenloy & Yellon, 2004, 2007a, 2007b). The latter describes
the phenomenonwhereby non-lethal ischaemia and reperfusion applied
to an organ or tissue remote from the heart protects the myocardium
from lethal reperfusion injury (Przyklenk et al., 1993; Whittaker &
Przyklenk, 1994; Dickson et al., 2000; Hausenloy & Yellon, 2008a,
2008b). Remote ischaemic conditioning (RIC) can be induced non-
invasively by inﬂating a blood pressure cuff placed on the arm or thigh
to above systolic pressure to induce brief ischaemia and then deﬂating
the cuff to allow reperfusion (Kharbanda et al., 2002). When adminis-
tered pre-hospital this has been shown to reduce myocardial infarct
size and improve myocardial salvage in PPCI patients (Botker et al.,
2010), and improve outcomes in patients undergoing cardiac surgery
or elective PCI (Gunaydin et al., 2000; Hausenloy et al., 2007; Hoole
et al., 2009). The mechanism of cardioprotection conferred by RIC is
so far unknown, but is thought to be due to a humoral factor that has
been shownby biochemical fractionation studies to be a protein between
3.5 kDa and 15 kDa in size (Serejo et al., 2007; Shimizu et al., 2009).
It is therefore proposed that in addition to its chronic effects SDF-1α
has a direct role in the protection observed from RIC and a proposed
paradigm is described in Fig. 1 (Saxena et al., 2008; Zaruba & Franz,
2010; Huang et al., 2011). Recently published data has demonstrated in-
creased SDF-1α in the serum of rats subjected to RIC. Furthermore, RIC,
which was shown to signiﬁcantly decrease infarct size and improve
papillary muscle functional recovery in an ex vivo model, could be
blocked by AMD3100, a highly speciﬁc inhibitor of CXCR4 (Davidson
et al., 2013; De Clercq, 2003). This, together with the identiﬁcation of
SDF-1α as an 8 kDa peptide has made it a prime candidate for a role
in RIC (Ceradini et al., 2004). In this review we focus on the evidence
for acute and chronic roles of SDF-1α in cardioprotection following
STEMI and discuss potential therapeutic manipulations of this mecha-
nism to protect against lethal tissue injury in the clinical setting. In par-
ticular we examine the role of inhibitors of the protease dipeptidyl
peptidase 4 (DPP-4) to prolong the half-life of SDF-1α to these ends.
2. Stromal derived factor 1α–CXC
Chemokine Receptor 4/CXC Chemokine Receptor 7
Chemokines, or chemoattractant cytokines, play a critical role in the
regulation and trafﬁcking of leukocytes as well as haematopoietic and
other progenitor cells (Ghadge et al., 2011). They are also involved in a
variety of other functions, including degranulation, mitogenesis, genetranscription, apoptosis, and angiogenesis (Gerard & Rollins, 2001).
There are over 50 human chemokines that are classiﬁed according to
the position of two N-terminal cysteine residues as CXC, CCC, C or CX3C
(Ghadge et al., 2011). In myocardial ischaemia, several chemokines,
including CXC and CC subtypes, have been shown to be up-regulated
in both experimental and clinical studies of myocardial infarction
(Matsumori et al., 1997; Riesenberg et al., 1997; Frangogiannis &
Entman, 2005; Takahashi, 2010; Ghadge et al., 2011).
SDF-1 (also known as CXCL12) is a CXC chemokine, so-called be-
cause the two amino acids nearest the N-terminus are separated by a
single amino acid (Rollins, 1997). It is a small (8 kDa), 89 amino acid
peptide that is encoded by a gene originally cloned from murine bone
marrow stromal cells, hence its name (Rollins, 1997; Ceradini et al.,
2004; Ghadge et al., 2011). It is highly conserved (more than 92% simi-
larity at the protein level) between species and has been shown to
confer protection between species (Shirozu et al., 1995; Shimizu et al.,
2009). Several isoforms of SDF-1, namely SDF-1α–ζ, arise from alterna-
tive splicing and have been identiﬁed by PCR (Ghadge et al., 2011). Of
interest here and best described is SDF-1α. Note that many studies do
not specify which isoform they are investigating and henceforth where
this is the case themore general SDF-1 descriptor is adopted. SDF-1α ex-
pression has been reported in several organs, tissues and cells, including
bonemarrow, heart, liver, kidney, thymus, spleen, skeletal muscle, brain
and, more recently, platelets (Kucia et al., 2005; Nagasawa et al., 1996;
Ratajczak et al., 2006; Ghadge et al., 2011; Chatterjee & Gawaz, 2013),
although it is likely that this also reﬂects expression in the vascular endo-
thelium of the organ. In the heart, SDF-1α is expressed by stromal cells,
endothelial cells and cardiomyocytes (Askari et al., 2003; Segret et al.,
2007). It is a chemoattractant for a variety of cell types including T lym-
phocytes, bone marrow stem cells (BMSCs; including haematopoietic,
endothelial and mesenchymal subtypes), adipose-derived regenerative
cells (ADRCs) and c-kit+ endogenous cardiac stem cells (eCSCs) (Aiuti
et al., 1997; Rollins, 1997; Kondo et al., 2009; Zaruba & Franz, 2010).
It also has a role in maintaining hematopoietic stem cell niches in
bone marrow (Ghadge et al., 2011). SDF-1α is cleaved from its active
form (1–68) to SDF-1α (3–68) by exopeptidases such as dipeptidyl
peptidase 4 (DPP-4), matrix metalloproteinase (MMP)-2 and MMP-9
(Segers et al., 2007). It has an estimated half-life in vivo by radiolabelling
of 25.8±4.6min (Misra et al., 2008). However, this represents total SDF-
1α only and does not differentiate active and inactive isoforms (Misra
et al., 2008). Similarly, commercially available ELISA kits, to our knowl-
edge, measure total and not active SDF-1α only and may therefore
offer a skewed view of the role of SDF-1α in myocardial infarction.
SDF-1α exerts its effects by binding the receptors CXCR7 and CXCR4,
for which it is the unique ligand (Balabanian et al., 2005; Sierro et al.,
2007). CXCR4 is a G protein coupled receptor that, once activated,
is thought to initiate a signalling cascade that regulates the functions
described (Kucia et al., 2004; Wong & Korz, 2008; Ghadge et al.,
2011). The SDF-1α–CXCR4 axis is also important in embryogenesis, in-
cluding cell migration and development of neuronal, cardiac, vascular,
haematopoietic and craniofacial systems, which is reﬂected by its ex-
pression on a range of progenitor cells, including haematopoietic, endo-
thelial and cardiac stem cells (Rollins, 1997; Zaruba & Franz, 2010;
Ghadge et al., 2011). During angiogenesis, expression of CXCR4 on ves-
sel endothelium correlates with areas of high SDF-1α expression
(McGrath et al., 1999). In embryonic development transgenic homozy-
gotemice lacking either CXCR4or SDF-1αhave abnormal B-lymphocyte
development, aswell as abnormal hepatic and cardiac development, in-
cluding ventricular septal defects, and die in utero (Nagasawa et al.,
1996; Tachibana et al., 1998; Zou et al., 1998). Similarly, in humans,
CXCR4 mutation causes impaired mobilisation of neutrophils and B-
cell lymphopaenia (Hernandez et al., 2003).
More recently it has become apparent that CXCR7 also plays a cen-
tral role in SDF-1α regulation. For example, Berahovich et al. found in-
creased serum SDF-1α in a murine model of genetic deletion and
pharmacological inhibition of CXCR7, which was associated with
Fig. 1. The SDF-1–CXCR4 signalling axis. Remote preconditioningmay enable both acute and chronic cardioprotective pathways (see text for details). SDF-1α, stromal derived factor-1α;
HIF-1α, hypoxic inducible factor-1α; ADRCs, adipose tissue derived regenerative cells; BMSCs, bonemarrow stem cells (including mesenchymal stem cells, hamatopoietic stem cells and
endothelial stem cells); ECSCs, endogenous cardiac stem cells; JAK, Janus kinase; STAT, signal transducer and activator of transcription; PI3K, phosphoinositide 3 kinase;MEK1/2,mitogen-
activated protein kinase; Erk, extracellular signal-regulated kinases; eNOS, endothelial nitric oxide synthase; NO, nitric oxide;mPKC,mitochondrial protein kinase C;mKATP,mitochondrial
ATP-sensitive potassium channel; ROS, reactive oxygen species; MPTP, mitochondrial permeability transition pore.
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relative contribution and relationship of CXCR4 and CXCR7 is not
fully elucidated. Hoffman et al. have demonstrated the rapid sponta-
neous internalisation of SDF-1α associated with CXCR7, compared to
G-protein coupling via CXCR4, and rapid release of SDF-1α degradation
products (Hoffmann et al., 2012). They also described a mechanism
whereby CXCR7 performs an SDF-1α-scavenging function (Hoffmann
et al., 2012). CXCR7 is thought to be up-regulated in inﬂammation,
cancer and autoimmune conditions (Sanchez-Martin et al., 2013). It
has been shown to improve migration and paracrine (angiogenesis
and mitogenesis) function of mesenchymal stem cells (MSCs) in mice
subjected to renal IR, and also reduced apoptosis and improved func-
tional recovery (Liu et al., 2012). Despite this its contribution, if any, to
cardioprotection is not yet known (Zaruba & Franz, 2010).
3. Chronic cardioprotection
3.1. Stromal derived factor 1α–CXC Chemokine
Receptor 4/CXC Chemokine Receptor 7 after acute myocardial infarction
Much is known about the SDF-1α–CXCR4/CXCR7 axis in the context
of myocardial regeneration after acute myocardial infarction (‘chronic
cardioprotection’). The mechanism is well described. In hypoxic condi-
tions, the transcription factor HIF-1α is up-regulated and in turn up-
regulates SDF-1α, CXCR4 and CXCR7 expression (Pillarisetti & Gupta,
2001; Zaruba & Franz, 2010; Ghadge et al., 2011; Esencay et al., 2013).
In this way SDF-1α acts as diffusible ‘homing beacon’ directing
cells towards hypoxic tissue. In health, since the bone marrow is physi-
ologically hypoxic, SDF-1α expression results in the retention of bonemarrow stem cells (Ceradini et al., 2004; Zaruba & Franz, 2010). In re-
sponse to acute myocardial infarction (AMI) several clinical studies
have demonstrated up-regulation of SDF-1α in infarct and peri-infarct
zones, returning to baseline at 7 days (Pillarisetti & Gupta, 2001;
Askari & Penn, 2003; Abbott et al., 2004; Hu et al., 2007), and in the
serum of patients suffering AMI (Yamani et al., 2005; Leone et al.,
2006). SDF-1α–CXCR4 signalling is also reportedly elevated in toxic
liver damage, total body irradiation and after chemotherapy (Kucia
et al., 2005). In AMI, this transient increase causes the gradient-guided
homing of progenitor cells from the bone marrow, as well as adipose
and cardiac tissue, to sites of injury and inﬂammation. Thus, expression
of SDF-1 in infarcted myocardium has been associated with recruit-
ment, retention, survival and proliferation of ADRCs, eCSCs and BMSCs
(Kucia et al., 2004; Unzek et al., 2007; Kondo et al., 2009; Jujo et al.,
2010; Tang et al., 2010; Zaruba & Franz, 2010; Penn et al., 2012). Con-
versely, decreased recruitment, angiogenesis and blood ﬂow has been
demonstrated when CXCR4 is blocked on infused progenitor cells or
SDF-1α is blocked in the recipient (Ceradini et al., 2004; Zaruba &
Franz, 2010). SDF-1α–CXCR4/CXCR7 exerts these effects by activating
intracellular signalling cascades (Zaruba & Franz, 2010). These include
the MAPK p42/44 extracellular signal-regulated (Erk1/2), PI3K-Akt,
JAK-STAT and protein kinase C (PKC) signalling cascades, as well as
inositol-1,4,5-triphosphate (IP3)-induced SR/ER calcium release
(Ratajczak et al., 2006; Haider et al., 2008; Gao et al., 2009; Zaruba &
Franz, 2010; Ghadge et al., 2011).
Although a number of mechanisms can mobilise stem cells, in-
cluding cytokines (granulocyte- and granulocyte macrophage-colony
stimulating factor (G-CSF, GM-CSF), and stem cell factor (SCF)), inter-
leukins (IL-7, IL-12, IL-3), chemokines (SDF-1α, IL-8), growth factors
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& Petit, 2002), and chemotherapeutic agents like cyclophosphamide
(Ghadge et al., 2011), it is suggested that the SDF-1α–CXCR4 axis is
the most potent and central to the process of mobilising progenitor
cells (Lapidot & Petit, 2002; Cottler-Fox et al., 2003). For example,
G-CSF, a cytokine known to increase the mobilisation of stem cells
from bone marrow and widely used therapeutically, does so by
disrupting the association of SDF-1 on bonemarrow stromal cells, oste-
oblasts and reticulocytes with CXCR4 on bone marrow stem cells (Petit
et al., 2002; Levesque et al., 2003; Zaruba & Franz, 2010). Interestingly, a
similar mechanism may explain how AMD3100, a selective CXCR4 an-
tagonist, increases circulating HPCs and endothelial progenitor cells
(Liles et al., 2003; Jujo et al., 2010).
3.2. Therapeutic application of stromal derived factor 1α–CXC
Chemokine Receptor 4/CXC Chemokine Receptor 7 in chronic cardioprotection
Given the potential therapeutic utility of SDF-1α it has been the
subject of several pre-clinical studies that have adopted a range of
approaches to manipulate SDF-1α expression. For example, SDF-1α
has been delivered by intracardiac injection immediately after AMI in
mice and demonstrated activation of Akt within endothelial cells
and cardiac myocytes, associated with improved cardiac function up
to 28 days after infarction, increased VEGF, increased angiogenesis and
reduced infarct size (Sasaki et al., 2007; Saxena et al., 2008). Continued
expression of active SDF-1α (peak at 7 days) has been achieved by
expression fromadenovirus injected in themyocardiumafter infarction,
which resulted in smaller infarct size, improved left ventricular param-
eters, less ﬁbrosis and a greater density of cardiomyocytes and blood
vessels in a rat model of STEMI (Tang et al., 2010). Other reported
techniques include intracardiac injection of skeletal myoblasts overex-
pressing human SDF-1α (Deglurkar et al., 2006; Elmadbouh et al.,
2007), MSCs overexpressing SDF-1α (Zhang et al., 2007; Zhao et al.,
2009), plasmid-based over-expression of SDF-1 (Sundararaman et al.,
2011), use of a PEGylated ﬁbrin patch for MSC transplantation (Zhang
et al., 2007), and MSCs overexpressing IGF-1 to activate SDF-1α
(Haider et al., 2008), all of which have conferred similar beneﬁcial
effects. Furthermore, some studies have utilised combinations of tech-
niques. For example, Askari et al. administered cardiac ﬁbroblasts
over-expressing SDF-1α to the infarcted myocardium of a rat along
with G-CSF and found improved stem cell homing, angiogenesis and
cardiac function (Askari et al., 2003). Abbott et al. found that stem
cells delivered to the coronary artery following AMI were only retained
alongside adenovirus-mediated cardiac expression of SDF-1α, an effect
that was abolished by AMD3100 (Abbott et al., 2004). Finally, Misao
et al. administered G-CSF or vehicle 3 days after IR in rabbits and
found increased serum SDF-1α, reduced infarct size, improved ejection
fraction (EF) and improved end-diastolic dimensions in the G-CSF
group, suggesting that G-CSF can increase SDF expression independent-
ly of its action on the SDF-CXCR4 association in bone marrow (Misao
et al., 2006). This was abrogated by AMD3100 (Misao et al., 2006).
Likewise, studies have attempted to manipulate CXCR4 expression.
Cheng et al. delivered MSCs overexpressing CXCR4 intravenously to
rats 24 h after IR and found improved homing, better preservation of
LV dimensions, reduced ﬁbrosis and better LV function, as assessed by
echocardiography (Cheng et al., 2008). Similarly, injection of cultured
stem cells with CXCR4 speciﬁcally up-regulated by cultivation led to
better angiogenesis (Shiba et al., 2009). Finally, conditional cardiomyo-
cyte CXCR4 null mice have been used to investigate the requirement
for CXCR4 signalling in stem cell-mediated repair following infarction
(Dong et al., 2012). In this study, exogenous MSC engraftment was
similar regardless of myocardial CXCR4 status, consistent with the hy-
pothesis that, in these animals, the myocardium still produces SDF-1
and the MSCs still express CXCR4 (Dong et al., 2012). The authors
noted abrogation of recovery of cardiac function following infarct in
CXCR4 deﬁcient mice, which may lend support to an acute role forSDF-1α, although infarct size was not measured acutely in this study
(Dong et al., 2012).
Despite these encouraging results enthusiasm is tempered by a
lack of ﬁrm evidence for true myocardial regeneration, and it may be
that the beneﬁts described above are solely attributable to paracrine
actions of SDF-1α (Ghadge et al., 2011). Furthermore, it is important
to note that not all experimental data indicates a favourable role
of SDF-1α–CXCR4 in AMI. For example, Pyo et al. found a negative
inotropic effect of SDF-1 on murine papillary muscles and cardiac
myocytes during calcium stimulation, an effect that was exacerbated
by adenovirus-mediated over-expression of CXCR4 but attenuated by
AMD3100 (Pyo et al., 2006). However, this data is contradicted by
data fromour laboratory showing that the functional recovery ofmuscle
treated with SDF-1 was signiﬁcantly improved relative to control mus-
cle (see Fig. 2) (Davidson et al., 2013). Elsewhere, SDF-1αwas injected
into the peri-infarct zone of pigs that, consistent with previous studies,
resulted in increased vessel density (Koch et al., 2006). However, there
was no signiﬁcant improvement in infarct size, myocardial perfusion or
left ventricular function compared to controls (Koch et al., 2006). These
studies may indicate a requirement for combination therapy to both
stimulate stem cell mobilisation from bonemarrow niches and homing
to sites of injury. In addition, Koch et al. delivered only a single bolus of
SDF-1, which could be expected to be rapidly proteolysed (Koch et al.,
2006), and administered SDF-1 at 7 dayswhile there is evidence that in-
travenous MSCs are only effective when given within 4 days (Maekawa
et al., 2004).
Nevertheless, research into the role of the SDF-1α–CXCR4 axis has
begun to be translated to the bedside. For example, Theiss et al. have
conﬁrmed in humans that mRNA of SDF-1 and HIF-1α, as well as stem
cell factor and vascular cell adhesion molecule, are signiﬁcantly higher
in explanted heart tissue of patients with ischaemic cardiomyopathy
versus dilated cardiomyopathy (Theiss et al., 2007). Penn's group have
recently completed a Phase I study of plasmid-based endomyocardial
SDF-1 delivery to 17 patients with symptomatic ischaemic cardiomyop-
athy and found improvements in 6-minute walk distance, New York
Heart Association classiﬁcation andquality of life (Pennet al., 2013). De-
spite these promising results, ejection fraction was non-signiﬁcantly
reduced in all patients and neither inﬂammation nor scar formation
was recorded, which may be relevant with serial myocardial injection.
4. Acute cardioprotection
4.1. Ischaemic preconditioning
Given the role of SDF-1α–CXCR4/CXCR7 in myocardial repair and
the involvement of signalling kinases known to be integral to ischaemic
conditioning, namely the Erk1/2, PI3K-Akt, JAK-STAT and PKC signalling
cascades (Deglurkar et al., 2006; Hausenloy &Yellon, 2008a), it has been
hypothesised that SDF-1αmay also be involved in the myocardial pro-
tection from IRI conferred by ischaemic conditioning. This is further
supported by studies that have successfully used ischaemic precondi-
tioning to up-regulate SDF-1α and improve stem cell engraftment
after AMI. For example, Tang et al. applied a preconditioning stimulus
directly to the heart in a murine model of AMI and demonstrated up-
regulation of CXCR4 on cardiac progenitor cells, increased cardiac
progenitor cell migration and recruitment, reduced infarct size and im-
proved functional outcome, all of which were abolished by the addition
of AMD3100 (Tang et al., 2009).
The pathophysiology of IRI is not fully understood, but proposed
mechanisms include oxidative stress (Zweier, 1988), deranged calcium
metabolism (Piper et al., 1998), rapid restoration of physiologic pH
(Lemasters et al., 1996), inﬂammation (Vinten-Johansen, 2004), and de-
ranged metabolism of glucose, insulin and potassium (Opie, 1970).
However, manipulation of thesemechanisms has largely failed to trans-
late to beneﬁt in clinical trials (Armstrong et al., 2007; Avkiran &
Marber, 2002; Bar et al., 2006; Baran et al., 2001; Boden et al., 2000;
Fig. 2. SDF-1α prior to ischaemia improves contractile recovery of rat heart papillary muscle that is isolated and subject to 30 min hypoxia and 2 h reoxygenation. Before hypoxia, the rat
papillary muscle was perfused with 1) SDF-1 for 10min; or 2) AMD3100 for 5 min then AMD3100 plus SDF-1 for 10min, or 3) AMD3100 alone for 15min. Control papillary muscle was
untreated. Data expressed as mean ± SE. The functional recovery of muscle treated with SDF-1 alone was signiﬁcantly improved (P b 0.05) (Davidson et al., 2013).
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et al., 2005; Mertens et al., 2006; Selker et al., 2012; Zeymer et al.,
2001). The ﬁnding that the myocardium could be protected from lethal
IRI by the application of multiple brief ischaemic episodes was ﬁrst
made by Murry et al., who found a 25% reduction in infarct size in
dogs subjected to four 5 minute circumﬂex occlusions, each separated
by 5min of reperfusion, prior to sustained occlusion of the circumﬂex ar-
tery (Murry et al., 1986). They termed this phenomenon ischaemic pre-
conditioning (IPreC) (Murry et al., 1986). However, despite promising
experimental results, its clinical utility is limited by the necessity to
intervene before the index ischaemia, which is evidently impossible to
predict in STEMI. Further work by Zhao et al. investigated repetitive is-
chaemia applied in early reperfusion of the left anterior descending
(LAD) territory in a canine model, and found a 14% reduction in infarct
size (compared to 15% in IPreC in their model), a technique referred
to as ischaemic post conditioning (IPostC) (Zhao et al., 2003). Several
studies have investigated this approach in a clinical setting, with mixed
results (Staat et al., 2005; Thibault et al., 2008; Lonborg et al., 2010;
Sorensson et al., 2010; Freixa et al., 2012; Tarantini et al., 2012).
The mechanism of protection conferred by ischaemic conditioning,
as it is currently understood, comprises extracellular autacoids acting
on cardiomyocyte receptors in response to the conditioning stimulus
and triggering protective intracellular signal transduction cascades
(Ovize et al., 2010). These are thought to unite at the mitochondria,
particularly the mitochondrial permeability transition pore (MPTP), to
inhibit apoptosis and preserve cardiomyocyte viability (see Fig. 1)
(Shanmuganathan et al., 2005).
Several endogenous extracellular factors are known to mitigate the
deleterious effects of IRI and are thought to play a central role in ischae-
mic conditioning (Simpkin et al., 2007; Smith et al., 2010; Hausenloy &
Yellon, 2013). They originate from a variety of sources, including
cardiomyocytes, endothelium, smooth muscle cells, nerve endings, in-
ﬂammatory cells, mast cells andmacrophages, in response to the condi-
tioning stimulus (Deussen et al., 1986; Dorge et al., 2002; Schulz et al.,
2004; Faigle et al., 2008; Heusch et al., 2008). They are thought to
have a number of actions, including reducing the activation of coronary
vascular endothelium, reducing the production of pro-inﬂammatory
cytokines and reactive oxygen species (ROS) and reducing adherence
of neutrophils to the coronary artery, all of which contribute to ischae-
mic conditioning (Zhao et al., 2003; Halkos et al., 2004; Ovize et al.,2010). As described, these factors exert these effects on the intracellular
effector by recruiting the same protein kinase signalling cascades
that are thought to be activated by the SFD-1α–CXCR4/CXCR7 axis
(Hausenloy & Yellon, 2004, 2007b; Ovize et al., 2010). The best deﬁned
of these are the ‘reperfusion injury salvage kinase’ (RISK) and ‘survivor
activating factor enhancement’ (SAFE) pathways (Hausenloy & Yellon,
2007a; Boengler et al., 2008; Lacerda et al., 2009; Lecour, 2009).
The RISK pathway was ﬁrst described by Yellon's group in recogni-
tion of the activation of PI3K-Akt pathway and p42/p44 Erk1/2 MAPK
by myocardial reperfusion (Yellon & Baxter, 1999; Brar et al., 2000;
Baxter et al., 2001; Jonassen et al., 2001; Hausenloy & Yellon, 2004).
Pharmacological activation of this pathway has been shown to reduce
infarct size by 40–50% at the time of reperfusion (Ovize et al., 2010). Im-
portantly, several of the known protective endogenous factors, includ-
ing insulin, insulin-like growth factor-1, bradykinin and adenosine,
have been shown to protect against IRI by recruiting the RISK pathway
(Hausenloy & Yellon, 2004). IPreC has also been shown to protect
against lethal IRI by recruiting the RISK pathway (Tong et al., 2000;
Fryer et al., 2001;Mocanu et al., 2002); speciﬁcally, the Akt1 isoform ap-
pears to be essential to IpreC as demonstrated in Akt1-deﬁcient mice
thatwere resistant to protection from IPreC (Kunuthur et al., 2012). Fur-
ther, it has been shown that the RISK pathway is recruited equally by
IPreC, IPostC and RIC, indicating that this signal transduction pathway
may represent a common pathway in ischaemic conditioning
(Hausenloy et al., 2003; Downey & Cohen, 2005; Hausenloy et al.,
2005; Tamareille et al., 2011).
Lecour et al. described an alternative pathway, labelled the SAFE
pathway, which activates JAK-STAT signalling (Lecour, 2009). In mice
subjected to simulated ischaemia and reperfusion, IPostC reduced in-
farct size and increased phosphorylated (active) STAT3 (Boengler
et al., 2008). In this study, administration of a speciﬁc JAK-2 inhibitor
(AG-490) reduced phosphorylated STAT3 and abolished the beneﬁcial
effect of IPostC (Boengler et al., 2008). Likewise, cardiac-speciﬁc
STAT3-deﬁcient mice were not protected from IRI by IPostC (Boengler
et al., 2008). Further, in a model of pharmacological preconditioning
with tumour necrosis factor-α cardioprotection was not affected by in-
hibition of PI3K-Akt or Erk 1/2MAPK, but was abolished by inhibition of
STAT3 (Lecour et al., 2005). Likewise, the SAFE signalling pathway is
also required for RIC (Tamareille et al., 2011). The interplay between
RISK and SAFE pathways is not fully deﬁned, however it has been
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IPostC was not only abolished by JAK-STAT inhibition, but also that
STAT3 inhibition decreased both functional STAT3 and Akt, suggesting
that these signalling cascades are not entirely independent (Goodman
et al., 2008). What is known is that both pathways converge on the mi-
tochondria, particularly the MPTP, to affect cardioprotection.
Many of the pathological processes thought tomediate IRI, including
oxidative stress, deranged calcium metabolism, and rapid recovery of
physiologic pH, exert their effects at the mitochondria, resulting in car-
diomyocyte death (Yellon & Hausenloy, 2007). Speciﬁcally, theMPTP, a
voltage- and calcium-dependent channel in the inner mitochondrial
membrane, is implicated (Ovize et al., 2010). This is closed in ischaemia
due to acidosis, a high mitochondrial membrane potential, and high
concentrations of Mg2+ and ADP (Di Lisa & Bernardi, 2009; Ovize
et al., 2010). However, in reperfusion, the MPTP opens in response to
binding of cyclophilin D (Cyp-D), which is potentiated by depolariza-
tion, increased mitochondrial Ca2+, inorganic phosphate and ROS, and
restoration of normal pH (Grifﬁths & Halestrap, 1995; Di Lisa et al.,
2001; Murata et al., 2001; Kim et al., 2006; Matsumoto-Ida et al.,
2006; Ovize et al., 2010). Once open, the mitochondrial membrane
rapidly dissipates, respiration becomes uncoupled, further elevating
ROS formation,whichestablishes a vicious cycle of furtherMPTP opening
and consequently loss of cell viability (Di Lisa & Bernardi, 2009; Ovize
et al., 2010). Importantly, it is known that IPreC and IPostC antagonise
MPTP opening and signiﬁcantly limit infarct size in animal models of
IR (Javadov et al., 2003; Hausenloy et al., 2004; Argaud et al., 2005;
Argaud et al., 2005; Bopassa et al., 2006; Zhao & Vinten-Johansen,
2006). Further, speciﬁc chemical inhibitors of MPTP, including NIM811
(Argaud et al., 2005; Argaud et al., 2005), cyclosporine A (Grifﬁths &
Halestrap, 1993, 1995; Hausenloy et al., 2004; Argaud et al., 2005), and
N-methyl-4-valine cyclosporine A (Hausenloy et al., 2004), have been
shown to reduce MPTP opening, limit apoptosis, improve functional re-
covery, and limit infarct size. Likewise, transgenic Cyp-D-deﬁcient mice
subjected to simulated IR have been shown to have reduced infarct
size (Baines et al., 2005; Nakagawa et al., 2005). The improvement in
functional recovery conferred by cyclosporine A, which prevents Cyp-D
binding (Ovize et al., 2010), has also been demonstrated in human atrial
tissue (Shanmuganathan et al., 2005), has been successfully translated to
a human pilot study of AMI (Piot et al., 2008), and a phase III trial is
currently recruiting (“Cyclosporine & Prognosis in Acute Myocardial
Infarction (MI) Patients (CIRCUS)”). Finally, it is notable that several
studies have associated activation of the RISK and SAFE pathways with
inhibition of MPTP opening, indicating it may represent the ﬁnal com-
mon effector of ischaemic conditioning (Bopassa et al., 2006; Davidson
et al., 2006; Juhaszova et al., 2004; Smith, Dixon et al., 2010; Zhao &
Vinten-Johansen, 2006).
4.2. Stromal derived factor 1α and ischaemic conditioning
SDF-1α has been shown to be involved in myocardial protection
from IRI conferred by ischaemic conditioning in a number of different
models (Hu et al., 2007; Huang et al., 2011; Jang et al., 2012). Data
from Yellon's group using ex vivo rat papillary muscle indicates that
SDF-1α increases recovery of function of muscle subject to simulated
IRI and can be blocked by AMD3100 (Fig. 2) (Davidson et al., 2013).
Similarly, Huang et al. administered SDF-1 5 min before ischaemia in
isolated mouse hearts subject to ischaemia–reperfusion in a model of
pharmacological preconditioning (Huang et al., 2011). They found that
SDF-1 signiﬁcantly improved functional recovery, reduced markers of
apoptosis and increased activation of STAT3, a central mediator of the
SAFE pathway (Huang et al., 2011). These effects were abolished by
the addition of AMD3100 (Huang et al., 2011). Interestingly, they did
not see any increase in Akt or Erk1/2 phosphorylation, and no attenua-
tion of protection with LY294002, an inhibitor of the Akt pathway
(Huang et al., 2011). However, the inhibitors were given prior to ischae-
mia and not prior to reperfusion and hence it may be that Akt is stillintegral to mitigating reperfusion injury speciﬁcally. Jang et al. used
an ex vivo Langendorff model of IR to show that SDF-1 infused from
10min before reperfusion to 30min afterwards reduced infarct size sig-
niﬁcantly more than that seen with IPreC and IPostC (Jang et al., 2012).
They also saw an increase in Erk phosphorylation at 5 and 20 min after
reperfusion, thereby implicating the RISK pathway in the mechanism
(Jang et al., 2012). Hu et al. demonstrated signiﬁcantly increased SDF-
1α released from isolated cardiac myocytes following hypoxia and re-
oxygenation that resulted in increased phosphorylation of both Erk1/2
and Akt, less lactate dehydrogenase release and less apoptosis (Hu
et al., 2007). Pre-treatment with AMD3100 abolished the effect on
myocyte survival (Hu et al., 2007). In vivo, they demonstrated pharma-
cological preconditioning with SDF-1α infused into the left ventricular
cavity signiﬁcantly reduced infarct size, which was abrogated by
AMD3100 (Hu et al., 2007). Conversely, Chen et al. used adenovirus-
mediated over-expression of CXCR4 administered 7 days prior to IR in
rats and found signiﬁcantly increased scar size, worse fractional short-
ening, increased inﬂammatory cell inﬁltration, increased cardiac
myocyte apoptosis and more left ventricular hypertrophy at 24 h
(Chen et al., 2010). These effects were attenuated by AMD3100, and it
is clear that the window for protection from IRI requires careful evalua-
tion (Chen et al., 2010).
4.3. Remote ischaemic conditioning
Despite promising results for mechanical IPreC and IPostC, the
common problem is that both mandate an invasive approach to
cardioprotection that may be both impractical and even harmful, as
they increase the risk of procedural complications, including access
site complications, coronary artery dissection or perforation, arrhyth-
mias and stroke. In response to these concerns RIC has emerged as an
exciting potential alternative, whereby brief cycles of ischaemia and re-
perfusion are applied to an organ or tissue remote from the heart. This
was ﬁrst shown to be protective by Przyklenk et al., 1993, who applied
four episodes of 5 minute circumﬂex occlusion separated by 5 min of
reperfusion, before 1 h of sustained LAD occlusion and reperfusion for
4.5 h in a caninemodel (Przyklenk et al., 1993). They found a 10% reduc-
tion in infarct size in the circumﬂex preconditioned dogs (Przyklenk
et al., 1993). This has been developed by others who showed similar
cardioprotective effects after applying a preconditioning stimulus to
other remote organs and tissues, including the kidneys and skeletal
muscle (Mcclanahan et al., 1993; Birnbaum et al., 1997), and using a
model of remote ischaemic postconditioning (Andreka et al., 2007).
More recently, it has been demonstrated that the non-invasive applica-
tion of brief cycles of ischaemia and reperfusion to a limb using a tour-
niquet has the same effect (Oxman et al., 1997; Kharbanda et al., 2002),
a ﬁndingwhich has greatly accelerated the rate of clinical trials demon-
strating RIC to be protective in a variety of clinical settings (Candilio
et al., 2013). These include prior to coronary artery bypass surgery
(CABG) (Gunaydin et al., 2000; Cheung et al., 2006; Hausenloy et al.,
2007; Venugopal et al., 2009; Thielmann et al., 2010; Hausenloy et al.,
2012; Thielmann et al., 2013), elective abdominal aortic aneurysm re-
pair (Ali et al., 2007;Walsh et al., 2009), elective cervical decompression
surgery (Hu et al., 2010), elective PCI (Hoole et al., 2009), and in PPCI for
STEMI (Kerendi et al., 2005; Schmidt et al., 2007; Botker et al., 2010). For
patients suffering STEMI, Botker et al. randomised patients to receive
PPCI with or without a pre-hospital RIC protocol. The primary endpoint
of improvedmyocardial salvage index at 30 days,measured bymyocar-
dial perfusion imaging, wasmet (Botker et al., 2010). Importantly, stud-
ies have demonstrated similar effects with RIC applied before
(Gunaydin et al., 2000; Hausenloy et al., 2007; Rentoukas et al., 2010),
during (Botker et al., 2010), and after the index ischaemia (Kerendi
et al., 2005; Andreka et al., 2007), thereby improving its clinical utility
and potential to mitigate IRI in patients.
It is suggested that the protective effect of RIC may be due to a hu-
moral factor(s), which may be one or a combination of the factors
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from the transiently ischaemic limb to the remote target organ where
they activate endogenous pro-survival signalling pathways. Evidence
for this comes from studies wherein the cardioprotective effect of RIC
applied to the lower limb is abrogated by occlusion of the femoral vein
(Lim et al., 2010). Further, infarct size is signiﬁcantly reduced when
the efﬂuent from an isolated perfused heart that is preconditioned
is used to perfuse a second isolated heart prior to index ischaemia
(Dickson et al., 1999; Leung et al., 2013). Interestingly, there also ap-
pears to be a neural component to RIC whereby severing the femoral
and sciatic nerve in an in vivo mouse model of IR abolishes the protec-
tion conferred by RIC, although the relationship between neural and
humoral components of this phenomenon is debated (Lim et al., 2010).
4.4. Stromal derived factor 1α and remote ischaemic conditioning
For the reasons described, SDF-1α is a prime candidate for a role in
RIC. Although only a limited number of studies have investigated the
possible role of SDF-1α–CXCR4 in RIC, it so far satisﬁes the criteria for
an endogenous mediator deﬁned by the Working Group of Cellular
Biology of the Heart of the European Society of Cardiology (Ovize
et al., 2010); namely that RIC can be abrogated by speciﬁc receptor
blockade or inhibition of the mediator's production and that RIC can
be mimicked by exogenous administration of the mediator. Jiang et al.
used remote ischaemic postconditioning to improve the retention of
improved MSCs in a murine model of myocardial infarction (Jiang
et al., 2013). They found increased serum and myocardial SDF-1α, sig-
niﬁcantly increased MSC retention in the myocardium, and improved
cardiac function at 1 month, all of which was abrogated by administra-
tion of anti-rat CXCR4 polyclonal antibody as a single intraperitoneal
injection after the RIC procedure (Jiang et al., 2013). Kamota et al. con-
ferred RIC using cyclical occlusion of the abdominal aorta in mice prior
to IR of the LAD territory (Kamota et al., 2009). They found increased
VEGF and SDF-1α acutely (1 and 3 h) and signiﬁcantly increased
CD34+ stem cells in the peripheral blood at 12 and 24 h (Kamota et al.,
2009). Both phases of protection independently resulted in improved
LV dimensions and function, and less apoptosis (Kamota et al., 2009).
Interestingly, blocking recruitment of bone marrow stem cells only
abrogated cardioprotection in the late phase in their model, which all
suggests that SDF-1α has the ability to potentially repair myocardial
damage, by directing the homing of stem cells from the bone marrow
to the site of damage, in combinationwith its potential to directly protect
the myocardium from IRI via the pathways described above. Most
recently, Davidson et al. demonstrated the involvement of SDF-1α in
acute RIC by showing that RIC signiﬁcantly reduced infarct size, an effect
which was blocked by AMD3100 (Davidson et al., 2013). The also con-
ﬁrmed that SDF-1α was elevated in the plasma of rats subjected to
hind-limb RIC (Davidson et al., 2013). Improved functional recovery in
isolated rat cardiac papillary muscle subjected to simulated IR after RIC
was also blocked by AMD3100 and in this model signiﬁcant functional
recovery was also seen with pharmacological preconditioning with
SDF-1α (Davidson et al., 2013).
5. Dipeptidyl peptidase-4 inhibitors
Despite these exciting results, an important drawback is the relative-
ly short plasma half-life of SDF-1α, which might limit its therapeutic
utility (Valenzuela-Fernandez et al., 2002; Segers et al., 2007). However,
bioengineered SDF-1 that is resistant to cleavage by DPP-4 and MMP-2
has been associated with improved stem cell homing, angiogenesis and
ejection fraction (Segers et al., 2007). Another approach to extracting
the maximum potential from SDF-1α relates to its potential manipula-
tion by a new class of anti-diabetic drugs. DPP-4 inhibitors such as
Sitagliptin, Vildagliptin, Alogliptin and Saxagliptin, have been designed
to prevent the breakdown of the incretin glucagon-like peptide 1
(GLP-1) by inhibiting the protease DPP-4 thereby increasing insulinand lowering glucose (Ravassa et al., 2012). Active SDF-1α is also
cleaved by DPP-4 and thus, similar to GLP-1, DPP-4 inhibition increases
the half-life of SDF-1α by preventing its degradation (Crump et al.,
1997; Zaruba et al., 2009). DPP-4 is found on many of the same cell
types as CXCR4, including B and T lymphocytes, endothelial cells and
CD34+ HPCs, as well as being present in plasma (Christopherson et al.,
2003; Zaruba & Franz, 2010).
Several studies have attempted to exploit this proteolytic mecha-
nism. Christopherson et al. ﬁrst showed that DPP-4 inhibition increased
stem cell homing to bone marrow (Christopherson et al., 2004), fol-
lowing which Zaruba et al. combined DPP-4 inhibition using Diprotin
A with G-CSF-mediated stem cell mobilisation in a murine model of
myocardial infarction (Zaruba et al., 2009). They found decreased
DPP-4 activity, which was associated with the stabilisation of active
SDF-1α (Zaruba et al., 2009). This consequently increased CXCR4+ EPCs
homing (an effect that was abrogated by administration of AMD3100),
reduced cardiac remodelling and apoptosis, and improved EF and sur-
vival (Zaruba et al., 2009). This approach was recently tested in a phase
III clinical trial using Sitagliptin (Safety and efﬁcacy of SITAgliptin plus
Granulocyte-colony-stimulating factor in patients suffering from Acute
Myocardial Infarction, SITAGRAMI). They randomised patients to either
G-CSF and Sitagliptin or placebo after PPCI for AMI in a multi-centre,
double-blind design. The primary endpoint of improved combined global
left and right ventricular ejection fraction as assessed by magnetic reso-
nance imaging was not met, and while there was a trend towards re-
duced major adverse cardiac events this was not signiﬁcant (“Safety
and efﬁcacy of SITAgliptin plus Granulocyte-colony stimulating factor in
patients suffering from Acute Myocardial Infarction — SITAGRAMI
trial”). This may be explained by the inclusion of only 21% of patients
with left ventricular ejection fraction below 50%, thereby obfuscating
any potential beneﬁt of this therapy.
Similarly, two large multicentre clinical trials have recently failed to
demonstrate a beneﬁt of DPP-4 inhibitors on cardiovascular outcomes
in patients with type 2 diabetes at high risk for cardiovascular events
(Scirica et al., 2013; White et al., 2013). For example, SAVOR-TIMI 53
compared Saxagliptin and placebo in 16,492 patients with a history of,
or at risk for, cardiovascular events (Scirica et al., 2013). After median
follow-up of 2.1 years they found no signiﬁcant difference in the prima-
ry endpoint of cardiovascular death, myocardial infarction or stroke.
Similarly, EXAMINE compared Alogliptin with placebo in 5380 patients
with type 2 diabetes and recent acute coronary syndrome (ACS) over
median follow-up of 18 months and found no signiﬁcant difference
in the primary endpoint of cardiovascular death, nonfatal myocardial
infarction or nonfatal stroke (White et al., 2013). That these important
studies failed to show any long-term beneﬁt of DPP-4 inhibitors is dis-
appointing, but may have several explanations. Patients in SAVOR-TIMI
53 had not necessarily had a recent ACS or other hypoxic stimulus to
SDF-1α production and it may be the case that, as in the preclinical
studies described, a combination of SDF-1α up-regulation and DPP-4
inhibition is necessary. In EXAMINE, although a recent ACS was an in-
clusion criteria, re-admissions with heart failure were not recorded.
It is equally important to note that these studies did not speciﬁ-
cally examine any acute role of DPP-4 inhibition, speciﬁcally on IRI.
Indeed, relatively few groups have done so. Kanki et al. developed a
bioengineered form of SDF-1 resistant to MMP-2 and DPP-4 (SSDF-
1(S4V)), which they injected into the LV cavity after reperfusion in a
rat model of IR (Kanki et al., 2011). This resulted in improved retention
in the ischaemic myocardium (Kanki et al., 2011). They also found
improved function and capillary density, although this was several
weeks after the initial insult making it difﬁcult to separate the relative
contribution of acute cardioprotection and possible cardiac regenera-
tion. It has also been demonstrated that the new anti-diabetic agents
described above have direct cardioprotective effects by preventing cell
death and limiting infarct size in ex vivo models (Hausenloy et al.,
2013). Hausenloy et al. pretreated control and diabetic rats with DPP-
4 inhibitors Vildagliptin or Sitagliptin and found a signiﬁcant reduction
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be dependent on elevated glucose and inhibited by Exendin, a GLP-1 re-
ceptor antagonist (Hausenloy et al., 2013). However, the contribution, if
any, of SDF-1–CXCR4 was not elucidated.
6. Conclusions
Reperfusion injury makes an important contribution to myocardial
injury and poor clinical outcomes after a lethal ischaemic insult in
animal models, although there remains a paucity of data from clinical
studies. Ischaemic conditioning has emerged as a powerful protective
phenomenon and has translated to the clinical application of remote
ischaemic conditioning, which is a clinically feasible, non-invasive,
cost-effective therapeutic intervention that has been shown tomitigate
acutemyocardial injury in preliminary studies. This has heralded a hunt
for the potential mechanism, which is thought to be due to a humoral
factor(s) carried from the preconditioned organ or tissue to the heart,
where endogenous pro-survival signalling pathways are activated.
SDF-1α confers protection against myocardial ischaemia–reperfusion
injury via the same signalling pathways implicated in ischaemic condi-
tioning, namely the RISK and SAFE pathways. It is also central to the
mobilisation and migration of stem cells and has been used to target
them to sites of ischaemic injury. SDF-1α therefore potentially has
pleiotropic effects on ischaemic myocardium: directly protecting via in-
tracellular pro-survival signal transduction pathways while activating
stem cell mobilisation and gradient-guided homing to augment myo-
cardial recovery. One potential avenue for translating these ﬁndings to
the bedside is with regard to the potentially signiﬁcant role of SDF-1α
in the mechanism of action of the anti-diabetic DPP-4 inhibitors
to protect the myocardium from lethal reperfusion injury. Finding
the factor(s) responsible for RIC is both novel and paramount for
maximising its potential in cardiac patients. Further work should
focus on clarifying the role of SDF-1α–CXCR4 in cardioprotection and
whether this can be mimicked using DPP-4 inhibitors acutely.
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